Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Monoclonal Antibodies Alzheimer's Disease Obesity Treatments Combination Therapy Eli Lilly GLP-1 Drugs Novo Nordisk Obesity Treatment Immunotherapy

Novo’s CagriSema Misses Non-Inferiority to Lilly’s Tirzepatide in 84-Week Head-to-Head Trial

Investor worries deepened, with Novo pointing to a late-2026 FDA decision alongside new trials to clarify the drug’s potential.

FDA Unveils ‘Plausible Mechanism’ Pathway for Individualized Gene and RNA Therapies

ImmunityBio Shares Rise on ANKTIVA Surge, Saudi Approval for Lung Cancer

Eli Lilly Rolls Out Monthlong Zepbound KwikPen on LillyDirect After FDA OK

FDA Approves Vanda's Bysanti for Schizophrenia and Bipolar I in Adults

Merck and Mayo Clinic Launch AI Drug Discovery Collaboration Using Platform_Orchestrate

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

FDA Rejects Disc Medicine’s Bitopertin for EPP After Questioning Surrogate Endpoint

Gilead Posts Q4 Beat on HIV Strength as 2026 Outlook Eases on Policy Headwinds

FDA Rejects Regenxbio’s Hunter Syndrome Gene Therapy Application

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

Merck Beats Q4 Forecasts as 2026 Guidance Trails Estimates on Patent Losses

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

Sanofi’s Venglustat Notches Gaucher Type 3 Phase 3 Win, Misses Fabry Pain Endpoint

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

EMA Panel Backs Conditional EU Approval for Rezurock in Chronic GvHD